IRESSA™ (gefitinib) in breast cancer patients

Study identifier:1839IL/0057

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase II trial to assess the efficacy of IRESSA™ (gefitinib) 500 mg/day in patients with breast cancer who have failed tamoxifen or have an oestrogen receptor negative tumour and would be considered for systemic therapy

Medical condition

Breast Cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

gefitinib (IRESSA™, ZD1839)

Sex

Female

Actual Enrollment

54

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Apr 2001
Primary Completion Date: -
Study Completion Date: 01 Oct 2005

Study design

Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Apr 2009 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria